# Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products

> **NCT06738485** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **CSL Behring** · enrollment: 60 (estimated)

## Conditions studied

- Congenital Hemophilia A

## Interventions

- **BIOLOGICAL:** Recombinant single-chain factor VIII (rVIII-SingleChain)

## Key facts

- **NCT ID:** NCT06738485
- **Lead sponsor:** CSL Behring
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-09
- **Primary completion:** 2026-10-26
- **Final completion:** 2026-10-26
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06738485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06738485, "Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06738485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*